Repeated endocrinological tests showed central hypothyroidism [thyroid-stimulating hormone (TSH): 0.460 μU/ml; T4: 0.87 ng/dl] and GH deficiency [GH: 0.92 ng/ml, insulin-like growth factor 1 (IGF-1) <15 μg/L]; therefore, subcutaneous GH (0.028 mg/kg/day) and oral levothyroxine (3.5 μg/kg/day) were started. This evidence concerns the gene GH1 and Central hypothyroidism.